Patient Newsletters

As a participant on the BADBIR study, you might like to know how the study is progressing, and how your participation is contributing to psoriasis research. Our latest newsletter for 2023 is now available for you to download and view. You’ll also find our previous newsletters here.

2023

The 2023 BADBIR Patient Newsletter discusses updates on psoriasis treatment safety and effectiveness using data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Key topics include genetic factors in psoriasis treatment, comparisons of treatment outcomes, the use of artificial intelligence to optimize treatment, and the effectiveness of biologic therapies. The newsletter also highlights patient portal improvements, and real-world data on conventional and biologic treatments, as well as the impact on quality of life. It emphasizes ongoing research and patient participation.

2020

The 2020 BADBIR Patient Newsletter focuses on psoriasis treatment safety and effectiveness. It covers how patient contributions aid research, compares biologics like Stelara, Humira, and Enbrel, and discusses real-world treatment results. The newsletter addresses COVID-19’s impact on psoriasis, provides data on treatment duration, infection risks, and cardiovascular events, and highlights research on biologics and cancer risks. It also touches on personalized treatment options based on various factors like weight and disease severity.

2019

The 2019 BADBIR Patient Newsletter highlights the expansion of drug safety research, including new biologics and small molecule therapies for psoriasis. It covers recent research on infection risks, biologic drug survival rates, and treatment adherence. The newsletter also discusses the introduction of a depression screening tool, data collection updates, and cancer risk research related to long-term biologic use. Additionally, it emphasizes the importance of real-world patient data in shaping treatment safety and effectiveness.

2017

The 2017 BADBIR Patient Newsletter focuses on research into the long-term safety of biologic and conventional treatments for psoriasis. It highlights the growing number of patients participating in BADBIR, the approval of new drugs like Taltz, and findings from key research papers. Topics include patterns in biologic therapy use, factors influencing the choice of biologic treatments, and the effectiveness of biologics in improving patients’ quality of life. The newsletter also celebrates 10 years of data collection and research progress.

2016

The 2016 BADBIR Patient Newsletter focuses on the long-term safety of biologic therapies for psoriasis. It provides updates on patient enrollment, discusses treatment comparisons between biologics and conventional therapies, and highlights key research findings on comorbidities such as obesity and depression. The newsletter also covers the importance of patient contributions in improving psoriasis treatments, and it includes detailed analyses of biologic drug survival rates, outlining how long patients typically stay on therapies like Humira, Enbrel, Remicade, and Stelara.